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Background and Aims: Several treatment approaches exist for early stage hepatocellular 
carcinoma (HCC).  We aimed to assess the benefits and harms of different treatment modalities for 
Barcelona Clinic Liver Cancer (BCLC) stage 0 (very early) and A (early) HCC by performing a network 
meta-analysis (NMA) using Cochrane methodology. 
 
Methods: The Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Science 
Citation Index Expanded, WHO International Clinical Trials Registry Platform and randomised clinical 
trials (RCTs) registers were searched to identity 6033 trials. Only RCTs with BCLC stages 0 or A HCC 
were included. RCTs were excluded if participants had previously undergone liver transplantation or if 
technical variations of the same modality were compared. Two review authors independently 
identified trials and extracted data. The primary outcome was mortality at maximal follow-up.  We 
were unable to perform the intended NMA due to lack of comparative data. Therefore, we calculated 
the odds ratio (OR), rate ratio (RR), or hazard ratio (HR) with 95% confidence intervals (CI) based on 
an available-case analysis. 
 
Results: 3126 participants from 18 RCTs were suitable for inclusion with a follow-up of 6-42 months, 
during which 30% died.  Most deaths occurred after 3 years of follow-up. The quality of included 
RCTs was generally low. Compared to radiofrequency ablation (RFA), higher mortality was seen with 
percutaneous acetic acid injection (PAI, HR 1.77, CI 1.12-2.79) and percutaneous alcohol injection 
(PEI, HR 1.49, CI 1.118- .88).  No difference in mortality at maximal follow-up was observed in RFA 
vs surgery, or any other comparisons between treatments. In non-surgical candidates, PEI resulted in 
higher cancer-related mortality (OR 2.18, CI 1.22-3.89) and distal/local HCC recurrence (OR 1.56, CI 
1.02-2.45) than RFA. Participants who had surgery had lower distal/local HCC recurrence (OR 0.52, 
CI 0.35-0.78) and lower HCC recurrence in the liver (OR 0.49, CI 0.31-0.78) than those who had 
RFA.  In addition, RFA resulted in fewer adverse events (RR 4.42, CI 2.74-7.15), fewer serious 
adverse events (RR 7.02, CI 2.29-21.46) and shorter length of stay (mean 8.42 days, CI 7.84-9.01). 
 
Conclusions: RFA appears to be superior to PEI and PAI in terms of mortality.  In non-surgical 
candidates, RFA has lower cancer-related mortality and recurrence than PEI.   In surgical candidates, 
RFA has fewer complications and shorter length of stay but higher recurrence rates.  Further high 
quality RCTs are required in this group.  
  
